Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKesson
Harvard Business School
McKinsey
Baxter

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SUVN-G3031

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug SUVN-G3031: Sponsors, patents, clinical trial progress

SUVN-G3031 is an investigational drug.

There have been 7 clinical trials for SUVN-G3031. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-six international patents.

Recent Clinical Trials for SUVN-G3031
TitleSponsorPhase
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without CataplexySuven Life Sciences LimitedPhase 2
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1

See all SUVN-G3031 clinical trials

Clinical Trial Summary for SUVN-G3031

Top disease conditions for SUVN-G3031
Top clinical trial sponsors for SUVN-G3031

See all SUVN-G3031 clinical trials

US Patents for SUVN-G3031

Glossary
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SUVN-G3031   Start Trial Compounds as histamine H3 receptor ligands Suven Life Sciences Limited (Hyderabad, IN)   Start Trial
SUVN-G3031   Start Trial Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride Suven Life Sciences Limited (Hyderabad, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Express Scripts
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
 NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews